# L&C Bio's ₩144.7 Billion Rights Offering Fully Subscribed

> L&C Bio's rights offering fully subscribed by shareholders, raising ₩150.35 billion for global expansion.
- Title: L&C Bio's ₩144.7 Billion Rights Offering Fully Subscribed
- Summary: L&C Bio's rights offering fully subscribed by shareholders, raising ₩150.35 billion for global expansion. L&C Bio's ₩144.7 billion rights offering fully…
- Keywords: l&c bio, seoul, dongtan integrated center, ritoo, megaderm, united arab emirates, united states, japan, singapore, thailand, peru, finance
- Source: BigGo Finance — https://finance.biggo.com/news/495a27ad-dc1b-4850-8241-7e22aaf68918
- Author: BigGo Finance
- Published: 2026-10-16T06:25:59+00:00
- Read time: 1 min
- Topics: l&c bio, seoul, dongtan integrated center, ritoo, megaderm, united arab emirates, united states, japan, singapore, thailand, peru, finance
## Subscription Results
L&C Bio achieved 103.92% subscription rate in its ₩144.7 billion rights offering, exceeding target shares.
## Final Subscription Amount
Final subscription reached ₩150.35 billion, surpassing target raise of ₩144.67 billion.
## Proceeds Allocation
72.6% of proceeds, or ₩105 billion, allocated to Dongtan Integrated Center construction.
## Earnings Growth
First-half revenue reached ₩69.1 billion, up 80.6% year-over-year with positive operating profit.
## Overseas Expansion
Secured UAE import approval and signed U.S. supply agreement worth at least $60 million.
## Next Steps
Bonus issue scheduled for listing on next month's 12th with record date on 27th.
## Key takeaway

L&C Bio's ₩144.7 billion rights offering fully subscribed by shareholders, raising ₩150.35 billion for Dongtan production center and overseas growth.